Cell differentiation inducer and application thereof
By using aconitine and 5-azacytidine in cell differentiation inducers, the problem of low action potential of cardiomyocytes differentiated by stem cells was solved, which significantly improved the electrophysiological characteristics of cardiomyocytes and enhanced their intracardiac repair application potential in.
Patent Information
- Application Number
- CN202411055032.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, cardiomyocytes differentiated from stem cells have the problem of low action potential, which limits their clinical application in cardiac repair.
Aconitine is used as a cell differentiation inducer, combined with 5-azacytidine, and through specific concentrations and treatment plans, stem cells are induced to differentiate into cardiomyocytes, improving the problem of low action potential, and avoiding the toxic effect of aconitine.
The action potential of differentiated cardiomyocytes is significantly improved, ensuring that their electrophysiological characteristics are close to normal cardiomyocytes, and enhancing their potential applications in cardiac repair.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a cell differentiation inducer and application thereof. Background Art
[0002] Sick Sinus Syndrome is a disease that may endanger the patient's life at any time, and its incidence increases with age. The use of stem cell-derived biological pacemakers can be achieved by restoring the pacing ability of the sinus node or creating an ectopic pacing area, providing an effective treatment strategy for this type of disease.
[0003] Stem cell induction mainly involves methods for differentiating stem cells (including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)) into cardiomyocytes. Common differentiation induction techniques include the use of specific growth factors and chemicals to induce stem cells to differentiate into cardiomyocytes, including the gradual addition of different signal molecules to simulate the natural environment during the development of cardiomyocytes. For example, 5-azacytidine (5-aza) can induce MSCs to differentiate into cardiomyocyte-like cells in vitro. As early as 1999, Canadian Tomita injected 5-aza-induced bone marrow mononuclear cells into a rat myocardial infarction model prepared by freezing, and found that there were bone marrow-derived cardiomyocyte-like cells in the scar tissue of the myocardium.
[0004] With the development of gene editing technology in recent years, there have been attempts to promote or guide the differentiation of stem cells into cardiomyocytes by manipulating specific genes. However, it is currently known that induction technology is difficult to solve the problem of low action potential of cardiomyocytes differentiated from stem cells, which limits its potential clinical application in cardiac repair. Summary of the invention
[0005] In order to solve the above problems, the present invention provides a cell differentiation inducer.
[0006] In a first aspect, the present invention provides a cell differentiation inducer comprising aconitine.
[0007] In one embodiment, the inducing agent further comprises 5-azacytidine.
[0008] In one embodiment, the concentration of aconitine is 1 µM.
[0009] In one embodiment, the 5-azacytidine concentration is 10 µM.
[0010] In a second aspect, the present invention provides a method for generating cardiomyocytes, comprising treating induced cells with 5-azacytidine and aconitine, so that the induced cells differentiate into cardiomyocytes.
[0011] In one embodiment, said generating cardiomyocytes is in vitro differentiation.
[0012] In one embodiment, 5-azacytidine is used to induce differentiation of the induced cells, and then aconitine is used to culture the differentiated induced cells.
[0013] In one embodiment, the induced cells are first induced to differentiate into cardiomyocyte-like cells using a culture medium containing 10 µM 5-azacytidine. After a certain induction time, the cells are rinsed and replaced with a complete culture medium without 5-azacytidine for continued culture; thereafter, the cells are cultured using a culture medium containing 1 µM aconitine.
[0014] In one embodiment, the induction time is 12-48 hours, the complete culture medium without 5-azacytidine is replaced and the culture is continued for 1-4 weeks, and then the culture medium containing 1 μM aconitine is used for 0.5-2 hours.
[0015] In one embodiment, the induction time is 24 hours, the complete culture medium without 5-azacytidine is replaced and the culture is continued for 3 weeks, and then the culture medium containing 1 μM aconitine is used for 1 hour.
[0016] In one embodiment, the induced cells comprise stem cells.
[0017] In one embodiment, the stem cells include mammalian stem cells, human stem cells, preferably, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
[0018] In a third aspect, the present invention also provides the use of the cell differentiation inducer or the method for producing cardiomyocytes in inducing the induced cells to differentiate into cardiomyocytes.
[0019] In the fourth aspect, the present invention also provides the use of the inducer described in the first aspect and the method for producing cardiomyocytes described in the second aspect in treating heart diseases in a subject, wherein the heart diseases include cardiomyopathy, coronary artery disease, heart failure, arrhythmia, myocardial infarction, endocarditis, arrhythmogenic right ventricular dysplasia (ARVD), long QT syndrome, catecholamine-sensitive polymorphic ventricular tachycardia (CPVT), Barth syndrome, and cardiac involvement in Duchenne muscular dystrophy, etc.
[0020] Technical effects of the present invention: 1. The inventors used aconitine for the first time to differentiate cardiomyocytes, which was able to significantly improve the problem of low action potential in differentiated cardiomyocytes.
[0021] 2. The inventors first determined the concentrations of the components of the cardiomyocyte inducer including aconitine, which can improve the problem of low action potential of cardiomyocytes while avoiding the toxic effects of aconitine. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Shown are the peak current densities at -40 mV in cardiomyocyte-like cells treated with aconitine (1 μM).
[0023] Figure 2 A comparison of the original current graphs of cardiomyocyte-like cells and cardiomyocytes after treatment with 1 μM aconitine is shown.
[0024] Figure 3 The changes in which 1 μM aconitine activated the Na current and shifted the IV curve downward are shown. DETAILED DESCRIPTION
[0025] 1. Overview The invention solves the problem of low action potential of induced differentiated cardiomyocytes in the prior art by adding aconitine treatment to the cardiomyocyte differentiation inducer.
[0026] 2. Definition For convenience, the meanings of some terms and phrases used in the specification, examples and appended claims are provided below. Unless otherwise specified or implied from the context, the following terms and phrases include the meanings provided below. Definitions are provided to help describe specific embodiments and are not intended to limit the claimed technology, as the scope of the technology is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the technology belongs. If there is a clear difference between the usage of a term in the art and its definition provided herein, the definition provided in the specification shall prevail.
[0027] The terms "subject", "object" and "individual" are used interchangeably herein and refer to animals, particularly humans, to which treatment (including prophylactic treatment) is provided. The term "subject" as used herein refers to humans and non-human animals. The terms "non-human animals" and "non-human mammals" are used interchangeably herein, including all vertebrates, such as mammals, such as non-human primates (particularly higher primates), sheep, dogs, rodents (e.g., mice or rats), guinea pigs, goats, pigs, cats, rabbits, cattle, and non-mammals, such as chickens, amphibians, reptiles, etc. In one embodiment of any aspect, the subject is a mammal. In another embodiment of any aspect, the subject is a human. In another embodiment of any aspect, the subject is an experimental animal or an animal substitute as a disease model. In another embodiment of any aspect, the subject is a domestic animal, including companion animals (e.g., dogs, cats, rats, pigs, guinea pigs, hamsters, etc.). The subject may have previously received treatment for the disease, or has never received treatment for the disease. The subject may have previously been diagnosed with the disease, or has never been diagnosed with the disease.
[0028] In a specific embodiment, the disease comprises a heart disease, specifically, cardiomyopathy, coronary artery disease, heart failure, arrhythmia, myocardial infarction, endocarditis.
[0029] As used herein, the term "human stem cell" refers to a human cell that can self-renew and differentiate into at least one different cell type. The term "human stem cell" encompasses human stem cell lines, human-derived induced pluripotent stem (iPS) cells, human embryonic stem cells, human pluripotent stem cells, human multipotent stem cells, amniotic stem cells, placental stem cells or human adult stem cells. In one embodiment of any aspect, human stem cells are not derived from human embryos.
[0030] The term "in vitro differentiation" refers to cells produced in culture, typically via stepwise differentiation from precursor cells such as human embryonic stem cells, induced pluripotent stem cells, early mesoderm, ectoderm or endoderm cells, or progenitor cells. Thus, for example, "in vitro differentiated cardiomyocytes" are cardiomyocytes produced in culture, typically via stepwise differentiation from precursor cells such as human embryonic stem cells, induced pluripotent stem cells, early mesoderm cells, lateral plate mesoderm cells, or cardiac progenitor cells.
[0031] As referred to herein, "treatment" of a condition or disease (e.g., cardiovascular disease) refers to a therapeutic intervention that enhances the function of cells, tissues, or organs, and / or enhances engraftment, and / or enhances transplantation or implant vascularization in the treated area, thereby improving the function of the tissue or organ (as a non-limiting example, the heart). That is, "treatment" is directed to the function of the tissue or organ being treated (e.g., enhanced function within the infarcted area of the heart), and / or other sites treated with the compositions described herein. Effective treatment does not need to cure or directly affect the underlying cause of the disease or condition to be considered to be effectively treated. For example, a treatment method that improves cardiac function, such as in terms of contraction strength or rhythm, can be an effective treatment without having to treat the cause of the infarct or arrhythmia.
[0032] As used herein, the term "disease" or "disorder" refers to a disease, syndrome or condition caused in part or in whole, directly or indirectly, by one or more abnormalities in the genome, physiology, behavior or health of a subject.
[0033] The disease or disorder can be a cardiac disease or disorder. Non-limiting examples of cardiac diseases include cardiomyopathy, arrhythmias, heart failure, arrhythmogenic right ventricular dysplasia (ARVD), long QT syndrome, catecholamine-sensitive polymorphic ventricular tachycardia (CPVT), Barth syndrome, and cardiac involvement in Duchenne muscular dystrophy.
[0034] As used herein, the term "comprising" means that there may be additional elements in addition to the defined elements presented. The use of "comprising" means including rather than limiting.
[0035] Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. 3. Specific embodiments The relevant equipment in the embodiments: phase contrast microscope, flow cytometer, cell culture incubator, fluorescence microscope, glass slide, EPC-10USB / Patchmaster patch clamp amplifier, IX73 inverted scientific research microscope, PERI-STARTMPRO microcirculation pump, MP-225 micromanipulator system, P-97 microelectrode pulling instrument, anti-vibration table, borosilicate glass electrode, constant temperature cell tank system are all owned by the laboratory; complete culture medium, 5-azacytidine, etc. are all commercially available.
[0037] Rats were purchased from Lesco Biotechnology Co., Ltd.
[0038] Example 1 5-Azacytidine induces stem cells to differentiate into cardiomyocytes (1) After the rats were euthanized, the tibia and femur were separated, the muscles and connective tissues were removed, and the bone marrow was flushed out with PBS. Red blood cell lysis solution was added to the flushed bone marrow and placed in the dark for 10 minutes. After centrifugation, total mononuclear cells (TNCs) were obtained. CD45 and CD106 were incubated at room temperature for 30 minutes. CD45-CD106+ cells were sorted by flow cytometry to obtain SMEs. After sorting, the obtained SMEs were cultured in a DMEM culture medium containing 10% fetal bovine serum in a 37°C, 5% CO2 incubator. During the proliferation of SMEs, the culture medium was replaced every three days, and the cells were subcultured after reaching about 80% fusion.
[0039] (2) SMEs were added to a culture medium containing 10 μM 5-azacytidine to induce differentiation of SMEs. After 24 hours, the culture medium was removed, the cells were rinsed twice with phosphate buffer, and the culture medium was replaced with complete culture medium without 5-azacytidine and cultured for another 3 weeks. During the culture process, the morphological changes of the cells were observed daily using a phase contrast microscope (Nikon TE2000) to determine whether they were consistent with differentiation into cardiomyocyte-like morphology. Example 2 Treatment of cardiomyocytes with aconitine to improve their action potential In order to detect the effect of aconitine treatment on cardiomyocyte-like cells, the inventors set up a control group (only 5-azacytidine was used to induce differentiation), an experimental group (5-azacytidine was used to induce differentiation and then continued to be treated with aconitine) and a cardiomyocyte group (normal cardiomyocytes).
[0040] 1. At room temperature (23-25°C), the Nav1.8 sodium channel current was recorded using the whole-cell voltage clamp technique. The whole-cell voltage clamp recording experiment used an Axon patch 700B patch clamp amplifier (purchased from Molecular Devices), the digital-to-analog converter was Digidata 1440A (Molecular Devices), and the glass microelectrode was pulled from a glass electrode blank (World Precision Instrunents) by a puller (Narishige). The tip resistance after perfusion of the electrode liquid was about 1.5-2.5 MΩ. The glass microelectrode was inserted into the amplifier probe to connect to the patch clamp amplifier. The clamping voltage and data recording were controlled and recorded by a computer using pClamp 10.2 data processing software (Molecular Devices), with a sampling frequency of 20 kHz and a filter frequency of 2 kHz.
[0041] 2. Preparation of solution Intracellular fluid (mM·L -1): K-aspartame acid 140mM, MgATP 4mM, MgCl21mM, EGTA10mM, GTP 0.1mM, HEPES10mM, KOH adjusted to pH 7.3.
[0042] Extracellular fluid (mM·L -1 ): NaCl 140mM, KCl 4mM, CaCl21mM, MgCl21mM, HEPES10mM, Glucose 5mM, NaOH adjusted to pH 7.4. Controlled by software (pCLAMP10.2), Digidata1440A digital-to-analog converter was used to collect stimulation signals and voltage input signals. After the cells were stabilized for 2-3 min after membrane rupture, they were stimulated again and the data before drug administration were recorded. After that, the drugs were perfused for 5 min and the data after drug administration were recorded. In order to avoid the attenuation of channel current affecting the experimental results, the experiment was completed within 20 min after cell membrane rupture. The sampled data were stored for measuring and analyzing the electrophysiological characteristics of the channel.
[0043] 3. Electrophysiological stimulation The electrophysiological stimulation subjects included three groups, including a cardiomyocyte group, a control group, and a 1 μM aconitine treatment group. The control group and the 1 μM aconitine treatment group were obtained by centrifuging the cardiomyocyte-like cells obtained in Example 1 and then grouping them.
[0044] The cells were clamped at -80mV, and a depolarizing voltage stimulus of +10mV was given for 20ms, and then repolarized to -80mV, with a stimulation frequency of 0.5Hz. The myocardial cell group and the control group were measured normally until the Nav1.8 sodium channel current was stable. The 1μM aconitine treatment group started the drug administration process after the current determined that the Nav1.8 sodium channel current was stable, until the cell current no longer changed.
[0045] The IV curve of the Na channel was drawn by using the INa current density (pA / pF) generated by each stimulation pulse in a single myocardial cell against the corresponding test voltage ( Figure 1 ),from Figure 1 It can be seen that the current density of the cardiomyocytes induced by differentiation with 10 μM 5-azacytidine (control group) was about -43, the current density of the normal cardiomyocyte group was about -72, and the current density of the experimental group induced by 10 μM 5-azacytidine was about -63, which was significantly lower than that of the control group. It can be seen that the treatment with aconitine significantly improved the current density of cardiomyocytes ( Figure 1 ).
[0046] The inventors also analyzed the original current of the experimental group and the normal myocardial cell group ( Figure 2 ), there is a significant difference between the cardiomyocyte group and the 1μM aconitine treatment, which indicates that the 1μM aconitine concentration treatment has an inductive effect on cardiomyocytes. With voltage as the horizontal axis and current density as the vertical axis, the IV curve of the sodium channel is drawn, see Figure 3 As can be seen from the figure, after treatment with 1 μM aconitine, the current density curve moved downward and became closer to the cardiomyocyte group, which shows that the treatment of cardiomyocytes with aconitine significantly improved the sodium ion channel.
[0047] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments may be modified, or some or all of the technical features thereof may be replaced by equivalents, without departing from the spirit and essence of the claims of the present invention; and these modifications or replacements are still within the scope defined by the claims of the present invention.
Claims
1. A cell differentiation inducer, characterized in that Contains aconitine.
2. The inducing agent according to claim 1, characterized in that The inducer also includes 5-azacytidine; The concentration of aconitine is 1µM; The 5-azacytidine concentration was 10 µM.
3. A method for producing cardiomyocytes, characterized in that: The method comprises treating the induced cells with 5-azacytidine and aconitine, so that the induced cells differentiate into cardiomyocytes.
4. The method according to claim 5, characterized in that The induced cells were first induced to differentiate using 5-azacytidine, and then the differentiated induced cells were cultured using aconitine.
5. The method according to claim 5 or 6, characterized in that First, the induced cells were induced to differentiate into cardiomyocyte-like cells using a culture medium containing 10 µM 5-azacytidine. After a certain induction time, the cells were rinsed and replaced with a complete culture medium without 5-azacytidine for continued culture; then, the cells were cultured using a culture medium containing 1 μM aconitine.
6. The method according to claim 7, characterized in that The induction time is 12-48 hours, and the complete culture medium without 5-azacytidine is replaced to continue culturing for 1-4 weeks, and then 1 μM aconitine culture medium is used for culturing for 0.5-2 hours.
7. The method according to claim 8, characterized in that The induction time was 24 hours, and the complete medium without 5-azacytidine was replaced to continue culturing for 3 weeks, and then the medium containing 1 μM aconitine was used for 1 hour.
8. The method according to claim 7 or 8, characterized in that The induced cells include stem cells. 9 . The method of claim 10 , wherein the stem cells include mammalian stem cells, human stem cells, and preferably, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
10. Use of the cell differentiation inducer according to any one of claims 1 to 4, or the method according to any one of claims 5 to 11, in inducing induced cells to differentiate into cardiomyocytes.
